Thread by @BRAINCURES

After 18 months, participants who received lecanemab scored, on average, 0.45 points better on the CDR-SB than those who got a placebo. Some researchers, however, have questioned whether this shift is big enough to make a noticeable difference in a person’s symptoms @meprillaman

https://twitter.com/profrobhoward/status/1598213519559761922

It’s a modest benefit, says @BrentForester, director of the Geriatric Psychiatry Research Program @McLeanHospital who helped to run the clinical trial for lecanemab. His concerns lie with safety. About 20% of treated people had brain-scan anomalies
#CTAD22

https://twitter.com/nature/status/1598346810413694982?s=21

If a connection between lecanemab and the deaths is found, it could pose “a real conundrum” for the US Food and Drug Administration as it decides how to rule on lecanemab, says Caleb Alexander @JohnsHopkinsSPH and an advisory committee member for the FDA
nature.com/articles/d4158…

@BrentForester is concerned, because, if approved, lecanemab would be given to people who are in the early stages of Alzheimer’s disease and therefore have not experienced much cognitive decline. Complications might therefore worsen their quality of life

https://twitter.com/braincures/status/1598986733915410432?s=21

“I honestly would be in the camp of not prescribing monoclonal antibodies” to people on anti-coagulation medicines, says @ApostolovaLiana, a neurologist at the Indiana University School of Medicine, who has consulted for @EisaiUS and @biogen @meprillaman
nature.com/articles/d4158…